Longitudinal tumor size and neutrophil‐to‐lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non‐small cell lung cancer treated …
S Gavrilov, K Zhudenkov, G Helmlinger… - CPT …, 2021 - Wiley Online Library
Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
[引用][C] Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung …
S Gavrilov, K Zhudenkov, G Helmlinger… - CPT: Pharmacometrics …, 2021 - elibrary.ru
Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer …
S Gavrilov, K Zhudenkov… - CPT …, 2021 - search.ebscohost.com
Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer …
S Gavrilov, K Zhudenkov… - CPT …, 2021 - pubmed.ncbi.nlm.nih.gov
Therapy optimization remains an important challenge in the treatment of advanced non-
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer …
S Gavrilov, K Zhudenkov, G Helmlinger… - CPT …, 2021 - search.proquest.com
Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer …
S Gavrilov, K Zhudenkov, G Helmlinger… - CPT …, 2020 - europepmc.org
Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
[HTML][HTML] Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung …
S Gavrilov, K Zhudenkov, G Helmlinger… - CPT …, 2021 - ncbi.nlm.nih.gov
Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …